Proteasome-dependent Processing of Topoisomerase I-DNA Adducts into DNA Double Strand Breaks at Arrested Replication Forks*

Reversible topoisomerase I (Top1)-DNA cleavage complexes are the key DNA lesion induced by anticancer camptothecins (CPTs) (e.g. topotecan and irinotecan) as well as structurally perturbed DNAs (e.g. oxidatively damaged, UV-irradiated, or alkylated DNA). It has been proposed that Top1 cleavage complexes arrest advancing replication forks, triggering the formation of DNA double strand breaks (DSBs) because of replication fork runoff at the Top1 cleavage complex sites on the leading strand. In this study, we show that the formation of replication-dependent DSBs requires the ubiquitin-proteasome pathway in CPT-treated cells. First, the proteasome inhibitor MG-132 specifically inhibited CPT-induced but not ionizing radiation- or hydroxyurea-induced DSBs as revealed by both the neutral comet assay and measurements of the specific DNA damage signals (e.g. γ-H2AX, phosphorylated ataxia telangiectasia mutated (Ser-1981), and phosphorylated Chk2 (Ser-33/35)) that are characteristic for DSBs. Knocking down the 20 S proteasome maturation protein also supported the requirement of the proteasome activity for CPT-induced DSBs. Second, CPT-induced DSB signals were shown to require ubiquitin, ubiquitin-activating enzyme (E1), a CUL-3-based ubiquitin ligase (E3), and the formation of Lys-48-linked polyubiquitin chains on Top1. Third, immunocytochemical studies revealed that the CPT-induced formation of γ-H2AX foci occurred at the replication forks and was attenuated by co-treatment with the proteasome inhibitor MG-132. In the aggregate, these results support a replication fork collision model in which Top1 cleavage complexes at the arrested replication forks are degraded by proteasome prior to replication fork runoff on the leading strand to generate DSBs.

[1]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[2]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[3]  A. Ciechanover,et al.  Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85 , 1984, Cell.

[4]  L. Liu,et al.  Tumor cell death induced by topoisomerase-targeting drugs. , 2001, Annual review of pharmacology and toxicology.

[5]  A. Ashworth,et al.  The proteasome is involved in determining differential utilization of double-strand break repair pathways , 2007, Oncogene.

[6]  B. Seliger,et al.  Expression, regulation and function of the ISGylation system in prostate cancer , 2009, Oncogene.

[7]  Y. Pommier,et al.  Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff , 2000, Molecular and Cellular Biology.

[8]  A. Tomida,et al.  Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex , 2004, Cancer Research.

[9]  S. Pestka,et al.  Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. , 2006, Cancer research.

[10]  L. Neckers,et al.  Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. , 2000, Biochemical pharmacology.

[11]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[12]  Y. Pommier,et al.  Repair of topoisomerase I-mediated DNA damage. , 2006, Progress in nucleic acid research and molecular biology.

[13]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. , 2006, Blood.

[14]  J. Champoux,et al.  Human Tdp1 Cleaves a Broad Spectrum of Substrates, Including Phosphoamide Linkages* , 2005, Journal of Biological Chemistry.

[15]  Chao-Po Lin,et al.  Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. , 2007, Cancer research.

[16]  Y. Pommier,et al.  Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes* , 2003, Journal of Biological Chemistry.

[17]  C. Brancolini,et al.  Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. , 2006, Cancer research.

[18]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[19]  R. Abraham,et al.  Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. , 2005, Molecular cell.

[20]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[21]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[22]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[23]  Y. Pommier,et al.  Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks* , 2006, Journal of Biological Chemistry.

[24]  W. McBride,et al.  The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism , 2005, BMC Cancer.

[25]  T. Ørntoft,et al.  Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer , 2006, British Journal of Cancer.

[26]  Ivan Dikic,et al.  Atypical ubiquitin chains: new molecular signals , 2008, EMBO reports.

[27]  J. Hayes,et al.  Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. , 2005, Molecular cell.

[28]  Chao-Po Lin,et al.  A Ubiquitin-Proteasome Pathway for the Repair of Topoisomerase I-DNA Covalent Complexes* , 2008, Journal of Biological Chemistry.

[29]  Elke Krüger,et al.  The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum , 2007, EMBO reports.

[30]  B. Giovanella,et al.  ISG15 as a novel tumor biomarker for drug sensitivity , 2008, Molecular Cancer Therapeutics.

[31]  A. Burgin,et al.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Liu,et al.  Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. , 1993, Cancer research.

[33]  Y. Pommier,et al.  Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. , 2002, Nucleic acids research.

[34]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[35]  L. Liu,et al.  A model for tumor cell killing by topoisomerase poisons. , 1990, Cancer cells.

[36]  J. R. Ferguson,et al.  The Nuclease Activity of Mre11 Is Required for Meiosis but Not for Mating Type Switching, End Joining, or Telomere Maintenance , 1999, Molecular and Cellular Biology.

[37]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[38]  H. Kimura,et al.  Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. , 2007, Cancer research.

[39]  Y. Pommier,et al.  The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses , 2007, Molecular and Cellular Biology.

[40]  M. Bjornsti,et al.  CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[42]  P. Coffino,et al.  Ubiquitin-proteasome system , 2004, Cellular and Molecular Life Sciences CMLS.

[43]  Chun-Yuan Ting,et al.  26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes* , 2001, The Journal of Biological Chemistry.

[44]  G. Cagney,et al.  Proteasome involvement in the repair of DNA double-strand breaks. , 2004, Molecular cell.

[45]  J. Wang,et al.  Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. , 1996, Molecular pharmacology.

[46]  K. Kohn,et al.  Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes , 1999, The EMBO journal.

[47]  Hui Zhang,et al.  Transcription-Dependent Degradation of Topoisomerase I-DNA Covalent Complexes , 2003, Molecular and Cellular Biology.